journal
MENU ▼
Read by QxMD icon Read
search

Journal of Thoracic Oncology

journal
https://www.readbyqxmd.com/read/28634123/clinical-utility-of-chromosomal-aneusomy-in-individuals-at-high-risk-of-lung-cancer
#1
Anna E Barón, Severine Kako, William J Feser, Heather Malinowski, Daniel Merrick, Kavita Garg, Stephen Malkoski, Shannon Pretzel, Jill M Siegfried, Wilbur A Franklin, York Miller, Holly J Wolf, Marileila Varella-Garcia
INTRODUCTION: Low dose CT screening for lung cancer has a high false positive rate with frequent discovery of indeterminate pulmonary nodules. Noninvasive biomarkers are needed to reduce false positives and improve risk stratification. A retrospective longitudinal evaluation was performed to assess chromosomal aneusomy in sputum via fluorescence in situ hybridization (CA-FISH) in four nested case-control studies. METHODS: ROC analysis resulted in two grouped cohorts: High Risk (CO High Risk and CO Nodule; 68 Cases, 69 controls) and Screening (ACRIN/NLST and PLuSS; 97 Cases, 185 controls)...
June 17, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28629896/randomized-phase-ii-study-of-preoperative-chemoradiotherapy-panitumumab-followed-by-consolidation-chemotherapy-in-potentially-operable-locally-advanced-stage-iiia-n2-non-small-cell-lung-cancer-nrg-oncology-rtog-0839
#2
Martin J Edelman, Chen Hu, Quynh-Thu Le, Jessica S Donington, Warren D D'Souza, Adam P Dicker, Billy W Loo, Elizabeth M Gore, Gregory M M Videtic, Nathaniel R Evans, Joseph W Leach, Maximilian Diehn, Steven J Feigenberg, Yuhchyau Chen, Rebecca Paulus, Jeffrey D Bradley
INTRODUCTION: Multimodality therapy has curative potential in locally advanced non-small cell lung cancer (LASCLC). Mediastinal nodal sterilization (MNS) after induction chemoradiotherapy (CRT) can serve as an intermediate marker for efficacy. NRG Oncology RTOG 0229 demonstrated the feasibility and efficacy of combining full dose radiation (61.2Gy) with chemotherapy followed by resection and chemotherapy. Based upon that experience and evidence that epidermal growth factor receptor (EGFR) antibodies are radiosensitizing, we explored adding panitumumab to CRT followed by resection and consolidation chemotherapy in LANSCLC with a primary endpoint of MNS...
June 16, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28629895/tumour-suppressor-micrornas-contribute-to-the-regulation-of-pd-l1-expression-in-malignant-pleural-mesothelioma
#3
Steven C Kao, Yuen Yee Cheng, Marissa Williams, Michaela B Kirschner, Jason Madore, Trina Lum, Kadir H Sarun, Anthony Linton, Brian McCaughan, Sonja Klebe, Nico van Zandwijk, Richard A Scolyer, Michael J Boyer, Wendy A Cooper, Glen Reid
INTRODUCTION: The upregulation of PD-L1 is found in many cancers and contributes to the evasion of the host's immune defence. In malignant pleural mesothelioma (MPM), PD-L1 expression is associated with non-epithelioid histological subtype and poor prognosis, but the pathways involved in the control of PD-L1 expression in MPM are poorly understood. To address one possible means of PD-L1 regulation we investigated the relationship between dysregulated microRNA levels and PD-L1 expression...
June 16, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28624467/comprehensive-analysis-of-egfr-mutant-abundance-and-its-effect-on-efficacy-of-egfr-tkis-in-advanced-nsclc-with-egfr-mutations
#4
Xuefei Li, Weijing Cai, Guohua Yang, Chunxia Su, Shengxiang Ren, Chao Zhao, Rongjun Hu, Xiaoxia Chen, Guanghui Gao, Zhiwei Guo, Wei Li, Caicun Zhou, Fred R Hirsch
BACKGROUND: It is not enough sensitive to use a qualitative detection method with sensitivity of 1% to determine EGFR status in advanced NSCLC and guide precise therapy in clinical practice. OBJECTIVE: To explore the relationship between the abundance of EGFR mutations and efficacy of EGFR-TKIs. METHODS: We used ARMS plus (ARMS+) to quantitatively evaluate the abundance of EGFR mutations in 201 advanced NSCLC patients. A cut-off value of the abundance of EGFR mutations was determined by ROC analysis in training group and was validated in validation group...
June 14, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28624466/resectable-clinical-n2-non-small-cell-lung-cancer-what-is-the-optimal-treatment-strategy-an-update-by-the-british-thoracic-society-lung-cancer-specialist-advisory-group
#5
Matthew Evison, Amelia Clive, Lianne Castle, Helen Powell, Rachel Thomas, Robert Buttery, Vidan Masani, Susan Harden, Doug West, Ian Woolhouse
Patients and clinicians are faced with uncertainty on the optimal treatment strategy for potentially resectable non-small cell lung cancer where there is clinical evidence of involvement of the ipsilateral mediastinum. Randomised controlled trials and meta-analyses have failed to demonstrate superiority of one bimodality strategy over another (chemotherapy plus surgery versus chemotherapy plus radiotherapy). One trial of trimodality treatment with chemotherapy, radiotherapy and surgery demonstrated an improvement in progression-free, but not overall, survival versus chemotherapy and radiotherapy...
June 14, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28627462/clinical-and-pathological-staging-validation-in-the-eighth-edition-of-tnm-classification-for-lung-cancer-correlation-between-solid-size-on-thin-section-computed-tomography-and-invasive-size-in-pathological-findings-in-the-new-t-classification
#6
Keiju Aokage, Tomohiro Miyoshi, Genichiro Ishii, Masahiro Kusumoto, Shogo Nomura, Shinya Katsumata, Keigo Sekihara, Tomoyuki Hishida, Masahiro Tsuboi
INTRODUCTION: The aim of this study was to validate the new 8th edition of the tumor-node-metastasis (TNM) classification and to elucidate whether radiological solid size corresponds to pathological invasive size incorporated in this T factor. METHODS: We analyzed the data of 1792 patients who underwent complete resection from 2003 to 2011 at the National Cancer Center Hospital East, Japan. We re-evaluated preoperative thin-sliced computed tomography (TSCT) to determine solid size and pathological invasive size using the 3rd edition of the WHO classification and reclassified them according to the new TNM classification...
June 13, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28611011/application-of-plasma-genotyping-technologies-in-non-small-cell-lung-cancer-a-practical-review
#7
REVIEW
Adrian G Sacher, Kimberly M Komatsubara, Geoffrey R Oxnard
The rational treatment of metastatic NSCLC hinges upon the timely detection of potentially targetable genomic alterations in order to guide therapy. Recent advances in highly sensitive genotyping technologies have allowed for the development of novel plasma genotyping assays which are capable of noninvasively detecting targetable alterations in plasma cell-free DNA without reliance on traditional tissue genotyping. The rapid development of plasma genotyping has led to an explosion in the number of assay platforms available from both commercial and laboratory sources...
June 10, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28611010/cases-of-alk-rearranged-lung-cancer-with-5-year-progression-free-survival-with-crizotinib-as-initial-precision-therapy
#8
Deepa Rangachari, Xiuning Le, Meghan Shea, Mark S Huberman, Paul A VanderLaan, Susumu S Kobayashi, Daniel B Costa
No abstract text is available yet for this article.
June 10, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28599887/phase-i-trial-of-cediranib-in-combination-with-cisplatin-and-pemetrexed-in-chemo-naive-patients-with-unresectable-malignant-pleural-mesothelioma-swog-s0905
#9
Anne S Tsao, James Moon, Ignacio I Wistuba, Nicholas J Vogelzang, Gregory P Kalemkerian, Mary W Redman, David R Gandara, Karen Kelly
BACKGROUND: In malignant pleural mesothelioma (MPM), targeting angiogenesis, with cediranib, a vascular endothelial growth factor receptor (VEGFR) and platelet derived growth factor receptor (PDGFR) inhibitor, may have therapeutic potential. METHODS: S0905 phase I combined cediranib (2 dose cohorts 30 mg and 20 mg daily) with cisplatin-pemetrexed for 6 cycles followed by maintenance cediranib in unresectable chemo-naïve MPM patients of any histologic subtype. The primary endpoint established the MTD in combination with cisplatin-pemetrexed in a dose de-escalation schema...
June 6, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28583587/management-of-multifocal-lung-cancer-results-of-a-survey
#10
Konstantinos Leventakos, Tobias Peikert, David Midthun, Julian R Molina, Shanda Blackmon, Francis C Nichols, Yolanda Garces, Christopher L Hallemeier, Stephen J Murphy, George Vasmatzis, Sarah L Kratz, William P Holland, Charles F Thomas, John J Mullon, K Robert Shen, Stephen D Cassivi, Randolph S Marks, Marie Christine Aubry, Alex A Adjei, Ping Yang, Mark S Allen, Eric S Edell, Dennis Wigle, Aaron S Mansfield
INTRODUCTION: Multifocal lung cancer (MFLC) is an increasingly common clinical scenario but there is lack of high-level evidence for its optimal treatment. Thus, we surveyed members of the interdisciplinary International Association for the Study of Lung Cancer (IASLC) on their therapeutic approaches and analyzed the resultant practice patterns. METHODS: We described the clinical scenario of an otherwise healthy 60 years old man with bilateral pulmonary nodules and asked the 6373 IASLC members whether they would recommend surgery, and if so, the extent of surgery...
June 2, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28576747/brief-report-long-term-outcome-of-surgery-or-stereotactic-radiotherapy-for-lung-oligometastases
#11
Joyce E Lodeweges, Theo J Klinkenberg, Jan F Ubbels, Harry J M Groen, Johannes A Langendijk, Joachim Widder
Local treatment for pulmonary oligometastases (one to five lesions) employing metastasectomy or stereotactic ablative radiotherapy (SABR) was investigated in a cohort having received multidisciplinary tumour-board-based treatment decisions. First choice of treatment was surgery, SABR was recommended in case of clinical adverse factors. Propensity-score adjusted and unadjusted overall survival (OS) was the primary endpoint, local control and time-to-failure of a local-only treatment strategy were also analysed...
May 30, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28576746/a-higher-proportion-of-the-egfr-t790m-mutation-may-contribute-to-the-better-survival-of-patients-with-exon-19-deletions-compared-with-those-with-l858r
#12
E-E Ke, Qing Zhou, Qiu-Yi Zhang, Jian Su, Zhi-Hong Chen, Xu-Chao Zhang, Chong-Rui Xu, Jin-Ji Yang, Hai-Yan Tu, Hong-Hong Yan, Yi-Chen Zhang, Fei-Yu Niu, Yi-Long Wu
INTRODUCTION: Increasing evidence has demonstrated that exon 19 deletions (Del19) and L858R mutation in EGFR have different prognostic and predictive roles in non-small-cell lung cancer (NSCLC). We aimed to investigate whether these 2 mutations produced differences in resistance mechanisms to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). METHODS: Consecutive patients with advanced EGFR-mutant NSCLC who acquired resistance to EGFR-TKIs and underwent post-progression biopsies were enrolled...
May 30, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28576745/lung-adenocarcinoma-manifesting-as-pure-ground-glass-nodules-correlating-ct-size-volume-density-and-roundness-with-histopathologic-invasion-and-size
#13
Benedikt H Heidinger, Kevin R Anderson, Ursula Nemec, Daniel B Costa, Sidhu P Gangadharan, Paul A VanderLaan, Alexander A Bankier
HYPOTHESIS: To quantify the relation between computed tomography (CT) size, volume, density, and roundness of lung adenocarcinomas (AC) manifesting as pure ground glass nodules (pGGNs) on CT, and to correlate these parameters with histologic features of invasiveness. METHODS: From 2005 to 2015, 63 ACs manifesting as pGGNs on CT were surgically resected at our institution. CT size was measured, and roundness, volumes and densities were computed. CT parameters were correlated to age and gender, as well as to size and number of invasive foci, and to histologic AC subcategories...
May 30, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28579481/scientific-advances-in-thoracic-oncology-2016
#14
REVIEW
Ross A Soo, Emily Ca Stone, K Michael Cummings, James R Jett, John K Field, Harry Jm Groen, James L Mulshine, Yasushi Yatabe, Lukas Bubendorf, Sanja Dacic, Ramon Rami-Porta, Frank C Detterbeck, Eric Lim, Hisao Asamura, Jessica Donington, Heather A Wakelee, Yi Long Wu, Kristin Higgins, Suresh Senan, Benjamin Solomon, Dong-Wan Kim, Melissa Johnson, James Ch Yang, Lecia V Sequist, Alice T Shaw, Myung-Ju Ahn, Daniel B Costa, Jyoti D Patel, Leora Horn, Scott Gettinger, Solange Peters, Murry W Wynes, Corinne Faivre-Finn, Charles M Rudin, Anne Tsao, Paul Baas, Ronan J Kelly, Natasha B Leighl, Giorgio V Scagliotti, David R Gandara, Fred R Hirsch, David R Spigel
Lung cancer care is rapidly changing with advances in genomic testing, the development of next-generation targeted kinase inhibitors, and the continued broad study of immunotherapy in new settings and potential combinations. The IASLC and the Journal of Thoracic Oncology publish this annual update to help readers keep pace with these important developments. Experts in thoracic cancer and care provide focused updates across multiple areas including prevention and early detection, molecular diagnostics, pathology and staging, surgery, adjuvant therapy, radiotherapy, molecular targeted therapy, and immunotherapy for non-small cell lung cancer, small cell lung cancer, and mesothelioma...
May 27, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28552766/the-influence-of-body-mass-index-on-overall-survival-following-surgical-resection-of-non-small-cell-lung-cancer
#15
Boris Sepesi, Kathryn A Gold, Arlene M Correa, John V Heymach, Ara A Vaporciyan, Jason Roszik, Ethan Dmitrovsky, Xi Liu
BACKGROUND: Population studies suggest that high body mass index (BMI) correlates with a reduced risk of death from lung cancer. The aim of our study was to evaluate definitively the influence of BMI on long term overall survival (OS) in surgical patients with non-small cell lung cancer (NSCLC). METHODS: Study population consisted of 1935 patients who underwent surgical resection for lung cancer at MD Anderson Cancer Center (2000-2014). Study variables included both patient and treatment related characteristics...
May 25, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28552765/comprehensive-analysis-of-the-discordance-of-egfr-mutation-status-between-tumor-tissues-and-matched-circulating-tumor-dna-in-advanced-non-small-cell-lung-cancer
#16
Rui Wan, Zhijie Wang, J Jack Lee, Shuhang Wang, Qingqing Li, Fuchou Tang, Jin Wang, Yu Sun, Hua Bai, Di Wang, Jun Zhao, Jianchun Duan, Minglei Zhuo, Tongtong An, Meina Wu, Zhaoli Chen, Zhenlin Yang, Jie Wang
INTRODUCTION: This study aimed to address the underlying reasons and clinical significance of the discordant epidermal growth factor receptor mutation (EGFRm) status between tumor tissues (T) and circulating tumor DNA (ctDNA, C). METHODS: Three groups of EGFR tyrosine kinase inhibitors (EGFR-TKIs) treated patients whose EGFRm were determined by Amplification Refractory Mutation System (ARMS) were included (Group A: EGFRm T+/C+; Group B: EGFRm T-/C+; and Group C: EGFRm T+/C-)...
May 25, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28535939/gene-expression-profiling-of-large-cell-lung-cancer-links-transcriptional-phenotypes-to-the-new-histological-who2015-classification
#17
Anna Karlsson, Hans Brunnström, Patrick Micke, Srinivas Veerla, Johanna Mattsson, Linnea La Fleur, Johan Botling, Mats Jönsson, Christel Reuterswärd, Maria Planck, Johan Staaf
INTRODUCTION: Large cell carcinoma with or without neuroendocrine features (LCNEC and LC, respectively) constitutes a small proportion of non-small cell lung cancer (NSCLC). The WHO2015 classification guidelines changed the definition of the debated histological subtype LC to be based on immunomarkers for adenocarcinoma and squamous cancer. We sought to determine if these new guidelines translate also to the transcriptional landscape of lung cancer, and LC specifically. METHODS: Gene expression profiling was performed using Illumina V4 HT12 microarrays on 159 cases (comprising all histological subtypes including 10 WHO2015 LC and 14 LCNEC tumors), with complimentary mutational and IHC data...
May 20, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28527899/egfr-mutation-analysis-for-prospective-patient-selection-in-two-phase-ii-registration-studies-of-osimertinib
#18
Suzanne Jenkins, James Chih-Hsin Yang, Pasi A Jänne, Kenneth S Thress, Karen Yu, Rachel Hodge, Susie Weston, Simon Dearden, Sabina Patel, Mireille Cantarini, Frances A Shepherd
INTRODUCTION: Osimertinib is an oral, CNS active, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for the treatment of EGFR T790M-positive advanced non-small cell lung cancer (NSCLC). Here we evaluate EGFR mutation frequencies in two Phase II studies of osimertinib (AURA extension and AURA2). METHODS: Patients with EGFR mutation-positive advanced NSCLC provided tumor samples following progression on their latest line of therapy for mandatory central T790M testing for study selection criteria...
May 17, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28506712/lung-metastases-from-esophageal-granular-cell-tumor-an-undoubted-criterion-for-malignancy
#19
Isidro Machado, Julia Cruz, Estanislao Arana, Juan Carlos Peñalver-Cuesta, Miguel Arraras-Martínez, Javier Lavernia, Antonio Llombart-Bosch
No abstract text is available yet for this article.
May 12, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28502724/durable-response-to-afatinib-in-lung-adenocarcinoma-harboring-nrg1-gene-fusions
#20
Nathan D Gay, Ying Wang, Carol Beadling, Andrea Warrick, Tanaya Neff, Christopher L Corless, Khaled Tolba
No abstract text is available yet for this article.
May 10, 2017: Journal of Thoracic Oncology
journal
journal
41363
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"